ClinicalTrials.gg
CompletedNCT02755649Updated Aug 20, 2020Results posted

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

A Phase 3 interventional study of Dupilumab and Matching Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
10th of 50
325 · median 75
Started
2016
the only one that year
Phase 3
11 of 50
none open now
Registered
15th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2016, is one of 11 in phase 3, and was the 15th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral Cyclosporine A (CSA), or when this treatment is currently not medically advisable.

The secondary objective is to assess the safety and tolerability of 2 dose regimens of dupilumab compared to placebo, administered with concomitant TCS, in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral CSA, or when this treatment is currently not medically advisable.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years or older
  2. Severe, Chronic AD, (according to American Academy of Dermatology Consensus Criteria [Eichenfield 2014]) for whom treatment with potent TCS is indicated
  3. EASI score ≥20 at the screening and baseline visits
  4. IGA score ≥3 (on the 0 to 4 IGA scale) at the screening and baseline visits
  5. ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits
  6. Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with TCS
  7. Have applied a stable dose of topical emollient (moisturizer) twice daily for at least the 7 consecutive days immediately before the baseline visit
  8. Documented history by a physician of either:

    1. No prior CSA exposure and not currently a candidate for CSA treatment due to:

      • medical (eg, uncontrolled hypertension on medication), or
      • use of prohibited concomitant medications (eg, statins, digoxin, macrolide, antibiotics, barbiturates, anti-seizure, nonsteroidal anti-inflammatory drugs, diuretics, angiotensin-converting-enzyme inhibitors, St John's Wort, etc), or
      • increased susceptibility to CSA-induced renal damage (elevated creatinine) and liver damage (elevated function tests), or
      • increased risk of serious infections, or
      • to CSA active substance or OR
    2. Previously exposed to CSA, and CSA treatment should not be continued or restarted due to:

      • intolerance and/or unacceptable toxicity (eg, elevated creatinine, elevated liver function tests, uncontrolled hypertension, paraesthesia, headache, nausea, hypertrichosis, etc), or
      • inadequate response to CSA (defined as flare of AD on CSA tapering after a maximum of 6 weeks of high dose [5 mg/kg/day] to maintenance dose [2 to 3 mg/kg/day] or a flare after a minimum of 3 months on maintenance dose). Flare is defined as increase in signs and/or symptoms leading to escalation of therapy, which can be an increase in dose, a switch to a higher-potency class of TCS, or the start of another systemic non-steroidal drug or
      • requirement for CSA at doses >5 mg/kg/day, or duration beyond those specified in the prescribing information (>1 year)

Exclusion criteria

Exclusion Criteria:

  1. Participation in a prior dupilumab clinical study
  2. Treatment with an drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before the screening visit
  3. and/or intolerance to or to any other ingredients contained in the TCS product used in the study
  4. Systemic CSA, systemic corticosteroids, or phototherapy within 4 weeks prior to screening, and azathioprine (AZA), methotrexate (MTX), mycophenolate mofetil (MMF), or Janus kinase (JAK) inhibitors within 8 weeks prior to screening
  5. Treatment with TCI within 1 week before the screening visit
  6. Treatment with biologics as follows:

    • Any cell-depleting agents including but not limited to rituximab: within 6 months before the screening visit, or until lymphocyte count returns to normal, whichever is longer
    • Other biologics: within 5 half-lives (if known) or 16 weeks prior to the screening visit, whichever is longer
  7. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks of the screening visit
  8. Treatment with a live (attenuated) vaccine within 12 weeks before the screening
  9. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the screening or superficial skin infections within 1 week before the screening visit. NOTE: patients may be rescreened no sooner than 2 weeks after infection resolves
  10. Known or suspected history of , including history of invasive opportunistic infections (eg, tuberculosis [TB], histoplasmosis, Listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution; or unusually frequent, recurrent, or prolonged infections, per investigator judgment
  11. Presence of any 1 of the following TB criteria:

    1. A positive tuberculin skin test at the screening visit
    2. A positive blood QuantiFERON®-TB or T-Spot test at the screening visit
    3. Chest x-ray (posterior-anterior and lateral views) at screening or within 3 months before the screening visit (radiology report must be available) with results consistent with prior TB infection (including but not limited to apical scarring, apical fibrosis, or multiple calcified granuloma). This does not include non-caseating granulomata.

    NOTE: Any of these 3 TB tests will be performed on a country-by-country basis according to local guidelines only if required by regulatory authorities or ethics boards.

  12. History of (HIV) infection or positive HIV serology at screening
  13. Positive surface antigen (HBsAg), hepatitis B core antibody (HBc Ab), or antibody (HCV Ab) at the screening visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Placebo QW + TCS

    Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).

    Drug: Matching Placebo

  • Experimental
    Dupilumab 300 mg Q2W + TCS

    Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg QW + TCS

    Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).

    Drug: Dupilumab

Interventions

  • Also known as: DUPIXENT®, REGN668, SAR231893

  • DrugMatching Placebo
06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16

    The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the Full Analysis Set (FAS) which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized).

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

    The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The analysis population for efficacy analyses is the FAS which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  2. Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16

    The Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  3. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16

    The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  4. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16

    Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of participants analyzed" = participants who were evaluable for this endpoint.

    Time frame: Baseline to Week 16

  5. Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  6. Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).

    Time frame: Baseline, Week 16

  7. Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score is indicative of a poor QOL. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  8. Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16

    The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  9. Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use

    The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  10. Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period

    The type, amount, frequency, and potency of topical products used during the study were recorded at home by participants in a medication diary. Participants returned TCS tubes at each clinic visit up until week 16, and these tubes were weighed by the site staff to determine the actual amount of TCS used. During the 16-week placebo-controlled study treatment period, medium-potency TCS dosing frequency was symptom-based (IGA score) adjusted every 4 weeks per the protocol-specified tapering algorithm. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number Analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline to week 16

  11. Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16

    The HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3, for possible scores ranging from 0 (no symptoms) to 21 (severe symptoms) for each of the anxiety and depression subscales. Recommended cut-off scores for both subscales to identify psychiatric distress are: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Scores less than 7 do not indicate psychiatric distress. Total score is the sum of the two sub-scores.

    Time frame: Baseline, Week 16

  12. Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16

    The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).

    Time frame: Baseline, Week 16

  13. Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)

    Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Full Analysis Set (FAS) included all randomized. Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 16

  14. Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2

    Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.

    Time frame: Baseline, Week 2

  15. Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period

    Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Safety analysis set (SAF) included all randomized participants who received any study drug; it was based on the treatment received (as treated).

    Time frame: Baseline to Week 16

  16. Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period

    Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

    Time frame: Baseline to Week 16

  17. Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period

    Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

    Time frame: Baseline to Week 16

  18. Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period

    Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

    Time frame: Baseline to Week 16

07

Results

Posted Aug 20, 2020

Participant flow

The study was conducted at 73 sites in Europe. A total of 390 participants were screened between 28 Jan 2016 and 14 Sep 2016. Of those, 325 participants were enrolled into the study and randomized. Sixty participants were considered screen failures, mostly due to unmet eligibility criteria.

Participant flow — Overall Study
MilestonePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Started108107110
Completed treatment (week 16)107106109
Completed study (week 28)788
Completed788
Not completed10199102
Withdrew: Transitioned into ole study9998100
Withdrew: Did not complete follow-up visits100
Withdrew: Physician decision002
Withdrew: Withdrawal by subject010
Withdrew: Undecided100

Outcome measures

PrimaryPercentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16

The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the Full Analysis Set (FAS) which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized).

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 1629.662.659.1
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level. P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by disease severity (IGA 3 vs IGA 4) and prior Cyclosporine A (CSA) use (Yes, No).) · Difference in percentages: 29.5 · 95% CI 16.87 to 42.05
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level. P-values were derived by Cochran-Mantel-Haenszel (CMH) test stratified by disease severity (IGA 3 vs IGA 4) and prior Cyclosporine A (CSA) use (Yes, No).) · Difference in percentages: 33 · 95% CI 20.41 to 45.57
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The analysis population for efficacy analyses is the FAS which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
Percent ChangePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16-46.6 ± 2.76-79.8 ± 2.59-78.2 ± 2.55
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Least square (ls) mean difference: -31.6 · 95% CI -38.85 to -24.3
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -33.1 · 95% CI -40.42 to -25.88
SecondaryPercent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16

The Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16
Percent ChangePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16-25.4 ± 3.39-53.9 ± 3.14-51.7 ± 3.09
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.2 · 95% CI -35.07 to -17.41
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference]: -28.5 · 95% CI -37.34 to -19.68
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16

The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16
Percent ChangePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16-29.5 ± 2.55-62.4 ± 2.48-58.3 ± 2.45
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -28.7 · 95% CI -35.56 to -21.93
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -32.9 · 95% CI -39.7 to -26.06
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16

Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of participants analyzed" = participants who were evaluable for this endpoint.

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16
Percentage of participantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 1614.345.740.4
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Difference in percentages: 26.1 · 95% CI 13.89 to 38.39
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Difference in percentages: 31.5 · 95% CI 19.08 to 43.83
SecondaryChange From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent BSA
Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16
Percent BSAPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16-19.57 ± 1.798-39.23 ± 1.715-37.52 ± 1.690
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -17.95 · 95% CI -22.706 to -13.197
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -19.66 · 95% CI -24.431 to -14.895
SecondaryPercentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 1613.940.239.1
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level) · Difference in percentages: 25.2 · 95% CI 13.99 to 36.41
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level) · Difference in percentages: 26.3 · 95% CI 14.95 to 37.65
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score is indicative of a poor QOL. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16
Score on a ScalePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16-4.5 ± 0.49-9.5 ± 0.46-8.8 ± 0.45
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -4.3 · 95% CI -5.6 to -3.04
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -5 · 95% CI -6.31 to -3.74
SecondaryChange From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16

The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16
Score on a ScalePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16-4.3 ± 0.62-11.9 ± 0.60-11.4 ± 0.59
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -7.1 · 95% CI -8.78 to -5.47
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -7.6 · 95% CI -9.29 to -5.97
SecondaryPercentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use

The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use26.458.056.5
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = = 0.0002 (Threshold for significance at 0.05 level.) · Difference in percentages: 30.1 · 95% CI 14.63 to 45.64
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.0001 (Threshold for significance at 0.05 level.) · Difference in percentages: 31.6 · 95% CI 16.11 to 47.05
SecondaryChange From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period

The type, amount, frequency, and potency of topical products used during the study were recorded at home by participants in a medication diary. Participants returned TCS tubes at each clinic visit up until week 16, and these tubes were weighed by the site staff to determine the actual amount of TCS used. During the 16-week placebo-controlled study treatment period, medium-potency TCS dosing frequency was symptom-based (IGA score) adjusted every 4 weeks per the protocol-specified tapering algorithm. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number Analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline to week 16
Reported as:
Least squares mean · Grams
Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period
GramsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period25.1 ± 1.4815.0 ± 1.5117.5 ± 1.49
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = = 0.0003 (Threshold for significance at 0.05 level) · Ls mean difference: -7.6 · 95% CI -11.64 to -3.51
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -10.1 · 95% CI -14.15 to -5.95
SecondaryChange From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16

The HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3, for possible scores ranging from 0 (no symptoms) to 21 (severe symptoms) for each of the anxiety and depression subscales. Recommended cut-off scores for both subscales to identify psychiatric distress are: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Scores less than 7 do not indicate psychiatric distress. Total score is the sum of the two sub-scores.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16
Score on a ScalePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16-2.3 ± 0.56-6.1 ± 0.54-5.2 ± 0.53
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = = 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -2.9 · 95% CI -4.41 to -1.43
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level) · Ls mean difference: -3.9 · 95% CI -5.38 to -2.4
SecondaryPercentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16

The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).

Time frame:
Baseline, Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 1625.966.455.5
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Difference in percentages: 29.5 · 95% CI 17.1 to 41.96
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = < 0.0001 (Threshold for significance at 0.05 level.) · Difference in percentages: 40.4 · 95% CI 28.24 to 52.61
SecondaryPercent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)

Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Full Analysis Set (FAS) included all randomized. Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)
Percent ChangePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)-29.0 ± 2.75-55.2 ± 2.66-53.3 ± 2.65
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -24.3 · 95% CI -31.63 to -16.88
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = < 0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.2 · 95% CI -33.49 to -18.86
SecondaryPercent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2

Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2
Percent ChangePlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2-10.0 ± 2.24-17.2 ± 2.25-19.7 ± 2.21
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · ANCOVA · p = = 0.0017 (Threshold for significance at 0.05 level) · Ls mean difference: -9.7 · 95% CI -15.8 to -3.66
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · ANCOVA · p = = 0.0214 (Threshold for significance at 0.05 level) · Ls mean difference: -7.2 · 95% CI -13.31 to -1.06
SecondaryPercentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period

Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Safety analysis set (SAF) included all randomized participants who received any study drug; it was based on the treatment received (as treated).

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period8.31.93.6
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = = 0.1486 · Difference in percentages: -4.7 · 95% CI -10.97 to 1.58
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.0319 · Difference in percentages: -6.5 · 95% CI -12.27 to -0.65
SecondaryPercentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period

Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period
Percentage of ParticipantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period1.91.91.8
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = = 0.9829 · Difference in percentages: 0 · 95% CI -3.6 to 3.53
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 1 · Difference in percentages: 0 · 95% CI -3.6 to 3.63
SecondaryPercentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period

Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period
Percentage of participantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period0.901.8
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = = 0.5619 · Difference in percentages: 0.9 · 95% CI -2.19 to 3.97
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.3241 · Difference in percentages: -0.9 · 95% CI -2.73 to 0.88
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period

Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).

Time frame:
Baseline to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period
Percentage of participantsPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period69.472.069.1
Statistical analysis
  • Placebo QW + TCS vs Dupilumab 300 mg QW + TCS · Cochran-Mantel-Haenszel · p = = 0.9518 · Difference in percentages: -0.4 · 95% CI -12.6 to 11.9
  • Placebo QW + TCS vs Dupilumab 300 mg Q2W + TCS · Cochran-Mantel-Haenszel · p = = 0.6833 · Difference in percentages: 2.5 · 95% CI -9.64 to 14.68

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of informed consent form up to end of study (EOS), Week 28, regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QW + TCS0/108 (0%)2/108 (1.9%)45/108 (41.7%)
Dupilumab 300 mg Q2W + TCS0/107 (0%)2/107 (1.9%)54/107 (50.5%)
Dupilumab 300 mg QW + TCS0/110 (0%)3/110 (2.7%)51/110 (46.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
Pancreatitis acuteGastrointestinal disorders0/1081/1070/110
HepatotoxicityHepatobiliary disorders0/1081/1070/110
HemiparesisNervous system disorders1/1080/1070/110
EmphysemaRespiratory, thoracic and mediastinal disorders1/1080/1070/110
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1080/1071/110
UreterolithiasisRenal and urinary disorders0/1080/1071/110
Dermatitis atopicSkin and subcutaneous tissue disorders0/1080/1071/110
Most frequent other events
Most frequent other events
EventPlacebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCS
NasopharyngitisInfections and infestations18/10822/10718/110
Dermatitis atopicSkin and subcutaneous tissue disorders18/1088/10710/110
Conjunctivitis allergicEye disorders7/10816/10710/110
ConjunctivitisInfections and infestations4/10812/1078/110
HeadacheNervous system disorders10/10810/10711/110
Rhinitis allergicRespiratory, thoracic and mediastinal disorders1/1087/1074/110

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean38.9 ± 13.3537.5 ± 12.8938.7 ± 13.2138.4 ± 13.13
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Female404244126
Male686566199
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean32.9 ± 10.8033.3 ± 9.9333.1 ± 11.0233.1 ± 10.56
Peak Weekly Averaged Pruritus Numerical Rating Scale (NRS) score
Peak Weekly Averaged Pruritus Numerical Rating Scale (NRS) score(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean6.4 ± 2.236.6 ± 2.106.2 ± 2.016.4 ± 2.11
Body Surface Area (BSA) Involvement of Atopic Dermatitis
Body Surface Area (BSA) Involvement of Atopic Dermatitis(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean55.0 ± 20.5156.1 ± 17.8356.0 ± 19.2655.7 ± 19.18
Global Individual Signs Score (GISS)
Global Individual Signs Score (GISS)(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean9.4 ± 1.639.3 ± 1.649.1 ± 1.639.3 ± 1.64
Dermatology Life Quality Index (DLQI) Total Score
Dermatology Life Quality Index (DLQI) Total Score(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean13.2 ± 7.6014.5 ± 7.6313.8 ± 8.0313.8 ± 7.75
Patient Oriented Eczema Measure (POEM)
Patient Oriented Eczema Measure (POEM)(Score on a Scale)Placebo QW + TCSDupilumab 300 mg Q2W + TCSDupilumab 300 mg QW + TCSTotal
Mean19.1 ± 5.9919.3 ± 6.2118.6 ± 6.9719.0 ± 6.40

5 further baseline measures are reported on the registry.

08

Study locations

73 sites
  • Site 1
    Vienna, Austria
  • Site 2
    Vienna, Austria
  • Brussels, Belgium
  • Leuven, Belgium
  • Loverval, Belgium
  • Site 1
    Berlin, Germany
  • Site 2
    Berlin, Germany
  • Site 3
    Berlin, Germany
  • Site 4
    Berlin, Germany
  • Site 5
    Berlin, Germany
  • Site 6
    Berlin, Germany
  • Site 7
    Berlin, Germany
  • Bochum, Germany
  • Site 1
    Dresden, Germany
  • Site 2
    Dresden, Germany
  • Site 3
    Dresden, Germany
  • Erlangen, Germany
  • Frankfurt am Main, Germany
  • Site 1
    Hamburg, Germany
  • Site 2
    Hamburg, Germany
  • Heidelberg, Germany
  • Kiel, Germany
  • Langenau, Germany
  • Leipzig, Germany
  • Lubeck, Germany
  • Magdeburg, Germany
  • Mahlow, Germany
  • Mainz, Germany
  • Muenster, Germany
  • Site 1
    Munchen, Germany
  • Site 2
    Munchen, Germany
  • Osnabrück, Germany
  • Selters, Germany
  • Stuttgart, Germany
  • Tubingen, Germany
  • Dublin, Ireland
  • Amsterdam, Netherlands
  • Utrecht, Netherlands
  • Site 1
    Bialystok, Poland
  • Site 1
    Bydgoszcz, Poland
  • Site 2
    Bydgoszcz, Poland
  • Gdansk, Poland
  • Site 1
    Katowice, Poland
  • Site 2
    Katowice, Poland
  • Site 3
    Katowice, Poland
  • Kielce, Poland
  • Site 1
    Krakow, Poland
  • Site 2
    Krakow, Poland
  • Site 1
    Lodz, Poland
  • Site 2
    Lodz, Poland
  • Site 3
    Lodz, Poland
  • Lublin, Poland
  • Szczecin, Poland
  • Warsaw, Poland
  • Site 1
    Warszawa, Poland
  • Site 2
    Warszawa, Poland
  • Site 1
    Wroclaw, Poland
  • Site 2
    Wroclaw, Poland
  • Zgierz, Poland
  • Chelyabinsk, Russian Federation
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Ryazan, Russian Federation
  • Saint Petersburg, Russian Federation
  • Kosice, Slovakia
  • Svidnik, Slovakia
  • Site 1
    Barcelona, Spain
  • Site 2
    Barcelona, Spain
  • Site 1
    London, United Kingdom
  • Site 2
    London, United Kingdom
  • Oxford, United Kingdom
  • Portsmouth, United Kingdom
  • Sheffield, United Kingdom
09

References and documents

Publications

  • Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Salle D, Hong CH, Sanchez-Carazo J, Foley P, Seo SJ, Msihid J, Chen Z, Cyr SL, Rossi AB. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatol Ther (Heidelb). 2021 Aug;11(4):1357-1372. doi: 10.1007/s13555-021-00558-0. Epub 2021 Jun 18. PubMed 34142350 ↗
  • Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaci D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212-1223.e6. doi: 10.1016/j.jaip.2020.12.059. Epub 2021 Jan 13. PubMed 33453450 ↗
  • Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis. 2021 Oct 1;32(1S):S81-S91. doi: 10.1097/DER.0000000000000698. PubMed 33165005 ↗
  • de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors. Br J Dermatol. 2018 May;178(5):1220-1221. doi: 10.1111/bjd.16348. Epub 2018 Mar 2. No abstract available. PubMed 29336016 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2017, 11 months.

Results were first posted in Aug 2020, 3 years 7 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2016
First posted
Apr 29, 2016
StartActual
Jan 31, 2016
Primary completionActual
Jan 4, 2017
CompletionActual
Mar 31, 2017
Results first posted
Aug 20, 2020
Last update
Aug 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02755649
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Jan 31, 2016
Primary completion
Jan 4, 2017
Completion
Mar 31, 2017
Results posted
Aug 20, 2020
Last update
Aug 20, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion